In this issue:
Osteoporosis risk with lymphoma treatments
Pretreatment SUVmax may influence benefit of BR vs R-CHOP in FL
CD4/CD8 T-cell selection affects CAR T-cell therapy
Venetoclax + LDAC for newly diagnosed AML
Ibrutinib + rituximab in first-line FL BTK inhibitor therapy in CLL resistant to venetoclax
IGHV mutational status and outcomes in CLL
Impact of pretransplant MRD on alloHCT outcomes in monosomal karyotype AML
Recommendations on HSCT for AML with FLT3-ITD
SCT in peripheral T-cell lymphoma NOS and angioimmunoblastic T-cell lymphoma
Please login below to download this issue (PDF)